Introduction
The Swiss Medical Board (SMB) published a report showing costs per quality adjusted life years (cost per quality-adjusted life year [cost/QALY]) to be extremely unfavourable (CHF 210 000/QALY) for statins in primary care in Switzerland when administered for a 5-year period. In its final report, the SMB recommended that statins should be used in primary preven-
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tion only if the SCORE risk is at least 7.5% over 10 years [1] . This is in contrast to current Swiss guidelines, which recommend that patients with a risk of 5% in 10 years for fatal cardiovascular disease may be offered statin medication.
In a Framingham Offspring Study, improved coronary risk stratification by the use of lower thresholds of coronary risk in younger subjects showed increased sensitivity at somewhat maintained specificity [2] . Further, higher levels of low density lipoprotein (LDL) cholesterol at the same risk levels improved prediction of who might benefit more from statins (an observation from the U.S. NHANES study [3] ). In the Copenhagen
General Population Study, a SCORE threshold of 2.4% appeared sufficiently sensitive for the treatment of those with future cardiovascular events [4] . In 3172 subjects hospitalised for a first myocardial infarction in Switzerland, the sensitivity of a SCORE threshold of 5% was only 37%, and only 16% of these 3172 subjects were on statin treatment when the myocardial infarction occurred [5] . Therefore, clinical evidence suggests that the SCORE threshold for starting statin treatment, based on prevention of cardiovascular events, should be lower than 5% in 10 years, but costs/QALY have not been reported for lower decision thresholds in Switzerland and Germany.
We first aimed to determine cost/QALY for various thresholds of SCORE risk, using the SMB assumptions, for treatment periods of 5 and of 10 years. Second, we looked at the risk distribution for SCORE in two large primary care populations with advanced carotid atherosclerosis and tried to define a sufficiently sensitive SCORE threshold.
Methods

Subject selection
The two groups of subjects were examined at a prac- 
Methods:
The SMB cost-efficiency model is applied to 10 rather than 5 years, and for different risk levels for vascular events. These SMB recommendations were studied in a population of 5144 healthy subjects from Germany and Switzerland, in whom the prevalence of advanced carotid atherosclerosis (total plaque area ≥80 mm 2 : TPA80) was assessed. 
Results
Computation of risk
Cardiovascular risk was computed with the published risk formulas in an excel spreadsheet (Excel, Microsoft, Richmond, USA), with use of SCORE for low risk populations [7] .
Effect model of the SMB
The SMB model for calculating cost/QALY is as follows. 
Effects of statins in primary care
The aggregated relative risk reduction per 1 mmol/l LDL reduction used by the SMB is 22% [8, 10] . This 22% 
Results
Study population description
On average, the Swiss group (n = 2203) included older subjects than the German group (n = 2942, 57 ± 9 vs 46 ± 10 years) and more women (49 vs 34%). The assessment of 10-year risk for both groups showed that most subjects were in the low risk category. The prevalence of TPA80 was higher in Switzerland (22 vs 15%). Lipid pro-
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files were comparable. Average coronary risk was low (table 1) .
Performance of various SCORE thresholds to detect TPA80
The proportion of subjects with TPA80 increased with increasing levels of SCORE ( Because the number of QALYs increased by a factor four when patients are treated for 10 instead of 5 years, the cost efficiency is exponentially influenced by the duration of treatment. Risk calculations are typically based on a 10-year period and, therefore, it is clinically more convincing to derive cost efficiency from 10 instead of 5 treatment periods in chronic noncommunicable diseases.
Second, in our cross-sectional observation of otherwise healthy subjects with advanced carotid atherosclerosis from Switzerland and Germany, we showed that the statin treatment recommendation of the SMB would leave virtually all these patients untreated, because at the age of 40-65 years, the decision level of SCORE 7.5% to initiate statin therapy would treat only 5 of 302 subjects with advanced atherosclerosis in Switzerland (sensitivity 2%) and 6 of 443 subjects with advanced atherosclerosis in Germany (sensitivity 1%, table 4). We found that in subjects aged 40-65 years and with advanced carotid atherosclerosis, TPA80 was detected with a sensitivity of only 28% when a SCORE threshold of 2.5% was used (Germany: 28%). The sensitivity decreased to <10% for SCORE thresholds of 5.0%
and 7.5% (table 4) . By consequence, reservation of Total cholesterol, mmol/l (mean ± 1 SD) 5.9 ± 1.2 5.9 ± 1.2 HDL cholesterol, mmol/l (mean ± 1 SD) 1.5 ± 0.5 1.4 ± 0.4 LDL cholesterol, mmol/l (mean ± 1 SD) 3.7 ± 1.0 3.8 ± 0.9
Triglycerides, mmol/l (mean ± 1 SD) 1.5 ± 0.9 1.7 ± 1.2 SCORE average risk in 10 years (% ± 1 SD) 1.5 ± 1.7 0.6 ± 0.3 PROCAM average risk in 10 years (% ± 1 SD) 6.2 ± 7. and CHF -5906, respectively, when the evidence-based purely relative risk reduction of 30% was used. Therefore, cost/QALY is acceptable at a SCORE risk of 2.5%, and three times lower than the recommendation of the SMB (table 2) . Table 3 : Coronary risk categories for SCORE by age groups, by the distribution of subjects with total plaque area ≥80 mm 2 (TPA80) and by country (Switzerland, n = 2124, or Germany, n = 2280). 
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CH-SCORE
Conclusion
By applying the SMB recommendation of SCORE 7.5%
for an eventual statin eligibility and using a very conservative calculation for treatment effects of Statins, such medication would virtually be eliminated from primary care.
With regard to the cost-efficiency analysis, the results of greater than CHF 210 000 reported by the SMB can only be applied to a SCORE risk of less than 1% in 5 years, with substantial increases in cost efficiency from a SCORE risk of 2.5% in 10 years (CHF 38 070/ QALY). The SMB recommendation is not derived from the cost model proposed and is very likely to pose a significant safety problem in subjects with low and intermediate cardiovascular risk, in whom 67% of first myocardial infarctions occur in Switzerland. Future guidelines should consider SCORE thresholds lower than 5% (e.g., 1.1-2.5%) for the initiation of statins in primary care for those aged 40-65 years.
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